ID   PMYT1_HUMAN             Reviewed;         499 AA.
AC   Q99640; B3KUN8; B4DXD4; D3DUA4; F8W164; I3L1V2; O14731; Q7LE24;
AC   Q8TCM9;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   15-MAR-2017, entry version 160.
DE   RecName: Full=Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Myt1 kinase;
GN   Name=PKMYT1; Synonyms=MYT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ENZYME REGULATION.
RX   PubMed=9268380; DOI=10.1074/jbc.272.35.22300;
RA   Booher R.N., Holman P.S., Fattaey A.;
RT   "Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but
RT   not Cdk2 activity.";
RL   J. Biol. Chem. 272:22300-22306(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=9001210; DOI=10.1128/MCB.17.2.571;
RA   Liu F., Stanton J.J., Wu Z., Piwnica-Worms H.;
RT   "The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine
RT   14 and localizes to the endoplasmic reticulum and Golgi complex.";
RL   Mol. Cell. Biol. 17:571-583(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4).
RC   TISSUE=Testis, and Thyroid;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-140; ARG-417 AND
RP   ALA-445.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 403-499 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   INTERACTION WITH PIN1.
RX   PubMed=9499405; DOI=10.1101/gad.12.5.706;
RA   Shen M., Stukenberg P.T., Kirschner M.W., Lu K.P.;
RT   "The essential mitotic peptidyl-prolyl isomerase Pin1 binds and
RT   regulates mitosis-specific phosphoproteins.";
RL   Genes Dev. 12:706-720(1998).
RN   [9]
RP   PHOSPHORYLATION, COMPONENT OF CDC2-CCNB1 COMPLEX, INTERACTION WITH
RP   PIN1, AND MUTAGENESIS OF ASP-251.
RX   PubMed=10504341;
RA   Wells N.J., Watanabe N., Tokusumi T., Jiang W., Verdecia M.A.,
RA   Hunter T.;
RT   "The C-terminal domain of the Cdc2 inhibitory kinase Myt1 interacts
RT   with Cdc2 complexes and is required for inhibition of G(2)/M
RT   progression.";
RL   J. Cell Sci. 112:3361-3371(1999).
RN   [10]
RP   FUNCTION, AND MUTAGENESIS OF ASN-238 AND 486-ARG--LEU-488.
RX   PubMed=10373560; DOI=10.1128/MCB.19.7.5113;
RA   Liu F., Rothblum-Oviatt C., Ryan C.E., Piwnica-Worms H.;
RT   "Overproduction of human Myt1 kinase induces a G2 cell cycle delay by
RT   interfering with the intracellular trafficking of Cdc2-cyclin B1
RT   complexes.";
RL   Mol. Cell. Biol. 19:5113-5123(1999).
RN   [11]
RP   PHOSPHORYLATION AT SER-426 AND THR-495.
RX   PubMed=12738781; DOI=10.1074/jbc.C300126200;
RA   Nakajima H., Toyoshima-Morimoto F., Taniguchi E., Nishida E.;
RT   "Identification of a consensus motif for Plk (Polo-like kinase)
RT   phosphorylation reveals Myt1 as a Plk1 substrate.";
RL   J. Biol. Chem. 278:25277-25280(2003).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-17; SER-94; SER-469 AND
RP   THR-495, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-120; SER-469 AND
RP   SER-473, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-17 AND SER-160, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-40; SER-94; SER-120;
RP   SER-143; SER-469 AND SER-482, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-103; CYS-140; HIS-246 AND LYS-351.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as a negative regulator of entry into mitosis (G2
CC       to M transition) by phosphorylation of the CDK1 kinase
CC       specifically when CDK1 is complexed to cyclins. Mediates
CC       phosphorylation of CDK1 predominantly on 'Thr-14'. Also involved
CC       in Golgi fragmentation. May be involved in phosphorylation of CDK1
CC       on 'Tyr-15' to a lesser degree, however tyrosine kinase activity
CC       is unclear and may be indirect. May be a downstream target of
CC       Notch signaling pathway during eye development.
CC       {ECO:0000269|PubMed:10373560, ECO:0000269|PubMed:9001210}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Negatively regulated by hyperphosphorylation
CC       during mitosis. The hyperphosphorylated form does not associate
CC       with CCNB1-CDC2 complexes. The PLK1 protein kinase may be required
CC       for mitotic phosphorylation. {ECO:0000269|PubMed:9268380}.
CC   -!- SUBUNIT: Interacts with CDC2-CCNB1 complex. Can also interact with
CC       PIN1 when phosphorylated by CDC2-CCNB1.
CC       {ECO:0000269|PubMed:10504341, ECO:0000269|PubMed:9499405}.
CC   -!- INTERACTION:
CC       P14635:CCNB1; NbExp=5; IntAct=EBI-495308, EBI-495332;
CC       P06493:CDK1; NbExp=4; IntAct=EBI-495308, EBI-444308;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:9001210}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9001210}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:9001210}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:9001210}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q99640-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q99640-2; Sequence=VSP_045699;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q99640-3; Sequence=VSP_046846;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q99640-4; Sequence=VSP_046847;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The membrane-association motif is essential for the
CC       localization to membrane of Golgi stack. According to some
CC       authors, it is a transmembrane domain; the existence of a
CC       transmembrane region is however unproven.
CC   -!- PTM: Autophosphorylated. Phosphorylated by CDC2-CCNB1 complexes on
CC       undefined serine and threonine residues. The phosphorylation by
CC       CDC2-CCNB1 complexes may inhibit the catalytic activity.
CC       {ECO:0000269|PubMed:10504341, ECO:0000269|PubMed:12738781}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. WEE1 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD28540.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pkmyt1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF014118; AAB71843.1; -; mRNA.
DR   EMBL; U56816; AAC50949.1; -; mRNA.
DR   EMBL; AK097642; BAG53500.1; -; mRNA.
DR   EMBL; AK098452; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK301926; BAG63346.1; -; mRNA.
DR   EMBL; AF549406; AAN40703.1; -; Genomic_DNA.
DR   EMBL; AC004233; AAC04478.1; -; Genomic_DNA.
DR   EMBL; AC004235; AAC04477.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85439.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85440.1; -; Genomic_DNA.
DR   EMBL; AL713779; CAD28540.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS10486.1; -. [Q99640-1]
DR   CCDS; CCDS45391.1; -. [Q99640-2]
DR   CCDS; CCDS58414.1; -. [Q99640-3]
DR   CCDS; CCDS58415.1; -. [Q99640-4]
DR   RefSeq; NP_001245379.1; NM_001258450.1. [Q99640-4]
DR   RefSeq; NP_001245380.1; NM_001258451.1. [Q99640-3]
DR   RefSeq; NP_004194.3; NM_004203.4. [Q99640-1]
DR   RefSeq; NP_872629.1; NM_182687.2. [Q99640-2]
DR   RefSeq; XP_011521036.1; XM_011522734.2. [Q99640-1]
DR   RefSeq; XP_011521037.1; XM_011522735.2. [Q99640-3]
DR   RefSeq; XP_011521038.1; XM_011522736.2. [Q99640-3]
DR   UniGene; Hs.732385; -.
DR   PDB; 3P1A; X-ray; 1.70 A; A=75-362.
DR   PDBsum; 3P1A; -.
DR   ProteinModelPortal; Q99640; -.
DR   SMR; Q99640; -.
DR   BioGrid; 114544; 19.
DR   IntAct; Q99640; 13.
DR   MINT; MINT-3059438; -.
DR   STRING; 9606.ENSP00000262300; -.
DR   BindingDB; Q99640; -.
DR   ChEMBL; CHEMBL3984; -.
DR   GuidetoPHARMACOLOGY; 2167; -.
DR   iPTMnet; Q99640; -.
DR   PhosphoSitePlus; Q99640; -.
DR   BioMuta; PKMYT1; -.
DR   DMDM; 55976573; -.
DR   EPD; Q99640; -.
DR   MaxQB; Q99640; -.
DR   PaxDb; Q99640; -.
DR   PeptideAtlas; Q99640; -.
DR   PRIDE; Q99640; -.
DR   DNASU; 9088; -.
DR   Ensembl; ENST00000262300; ENSP00000262300; ENSG00000127564. [Q99640-1]
DR   Ensembl; ENST00000440027; ENSP00000397739; ENSG00000127564. [Q99640-2]
DR   Ensembl; ENST00000573944; ENSP00000459123; ENSG00000127564. [Q99640-3]
DR   Ensembl; ENST00000574385; ENSP00000458943; ENSG00000127564. [Q99640-3]
DR   Ensembl; ENST00000574730; ENSP00000460868; ENSG00000127564. [Q99640-4]
DR   GeneID; 9088; -.
DR   KEGG; hsa:9088; -.
DR   UCSC; uc002csm.4; human. [Q99640-1]
DR   CTD; 9088; -.
DR   DisGeNET; 9088; -.
DR   GeneCards; PKMYT1; -.
DR   HGNC; HGNC:29650; PKMYT1.
DR   HPA; HPA068860; -.
DR   MIM; 602474; gene.
DR   neXtProt; NX_Q99640; -.
DR   OpenTargets; ENSG00000127564; -.
DR   PharmGKB; PA385; -.
DR   eggNOG; KOG0601; Eukaryota.
DR   eggNOG; ENOG410XS1M; LUCA.
DR   GeneTree; ENSGT00530000063230; -.
DR   HOGENOM; HOG000293277; -.
DR   HOVERGEN; HBG053623; -.
DR   InParanoid; Q99640; -.
DR   KO; K06633; -.
DR   PhylomeDB; Q99640; -.
DR   TreeFam; TF101087; -.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-69478; G2/M DNA replication checkpoint.
DR   SignaLink; Q99640; -.
DR   SIGNOR; Q99640; -.
DR   ChiTaRS; PKMYT1; human.
DR   EvolutionaryTrace; Q99640; -.
DR   GeneWiki; PKMYT1; -.
DR   GenomeRNAi; 9088; -.
DR   PRO; PR:Q99640; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000127564; -.
DR   CleanEx; HS_MYT1; -.
DR   CleanEx; HS_PKMYT1; -.
DR   ExpressionAtlas; Q99640; baseline and differential.
DR   Genevisible; Q99640; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:ProtInc.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IDA:HGNC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007067; P:mitotic nuclear division; TAS:ProtInc.
DR   GO; GO:0010923; P:negative regulation of phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0007088; P:regulation of mitotic nuclear division; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR016235; Tyr/Thr_kinase_Cdc2_inhib.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000567; TYPK_Myt1; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell cycle; Complete proteome; Endoplasmic reticulum; Golgi apparatus;
KW   Kinase; Magnesium; Membrane; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    499       Membrane-associated tyrosine- and
FT                                threonine-specific cdc2-inhibitory
FT                                kinase.
FT                                /FTId=PRO_0000086573.
FT   DOMAIN      110    359       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     116    124       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      398    499       Interaction with PIN1.
FT   REGION      437    499       Interaction with CDC2-CCNB1.
FT   MOTIF       382    398       Membrane-association motif.
FT   COMPBIAS      5     72       Pro-rich.
FT   ACT_SITE    233    233       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL       238    238       Magnesium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       251    251       Magnesium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   BINDING     139    139       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES      17     17       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES      40     40       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      94     94       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     120    120       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     143    143       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     160    160       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     426    426       Phosphoserine; by PLK1.
FT                                {ECO:0000269|PubMed:12738781}.
FT   MOD_RES     469    469       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     473    473       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     482    482       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     495    495       Phosphothreonine; by PLK1.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:12738781}.
FT   VAR_SEQ       1      9       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046846.
FT   VAR_SEQ       5     73       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046847.
FT   VAR_SEQ     439    499       SLSPEAVLARTVGSTSTPRSRCTPRDALDLSDINSEPPRGS
FT                                FPSFEPRNLLSLFEDTLDPT -> GHPPCLACPPAGLHSPL
FT                                RLSWPGLWGAPPPPGAGAHPGMPWT (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045699.
FT   VARIANT     103    103       E -> Q (in dbSNP:rs55834293).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041034.
FT   VARIANT     140    140       R -> C (in dbSNP:rs4149796).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019928.
FT   VARIANT     246    246       R -> H (in dbSNP:rs35192104).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041035.
FT   VARIANT     351    351       E -> K (in dbSNP:rs56382954).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041036.
FT   VARIANT     417    417       P -> R (in dbSNP:rs4149800).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019929.
FT   VARIANT     445    445       V -> A (in dbSNP:rs10546).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_019930.
FT   MUTAGEN     238    238       N->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:10373560}.
FT   MUTAGEN     251    251       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:10504341}.
FT   MUTAGEN     486    488       RNL->AAA: Loss of CDC2-CCNB1 interaction.
FT                                {ECO:0000269|PubMed:10373560}.
FT   CONFLICT    131    131       E -> A (in Ref. 4; BAG53500).
FT                                {ECO:0000305}.
FT   CONFLICT    415    415       G -> D (in Ref. 1; AAB71843).
FT                                {ECO:0000305}.
FT   CONFLICT    427    427       L -> F (in Ref. 1; AAB71843).
FT                                {ECO:0000305}.
FT   CONFLICT    491    491       L -> M (in Ref. 1; AAB71843).
FT                                {ECO:0000305}.
FT   STRAND      101    103       {ECO:0000244|PDB:3P1A}.
FT   HELIX       105    109       {ECO:0000244|PDB:3P1A}.
FT   STRAND      110    119       {ECO:0000244|PDB:3P1A}.
FT   STRAND      122    129       {ECO:0000244|PDB:3P1A}.
FT   TURN        130    132       {ECO:0000244|PDB:3P1A}.
FT   STRAND      135    144       {ECO:0000244|PDB:3P1A}.
FT   HELIX       148    164       {ECO:0000244|PDB:3P1A}.
FT   STRAND      173    179       {ECO:0000244|PDB:3P1A}.
FT   STRAND      182    188       {ECO:0000244|PDB:3P1A}.
FT   HELIX       194    201       {ECO:0000244|PDB:3P1A}.
FT   HELIX       207    226       {ECO:0000244|PDB:3P1A}.
FT   HELIX       236    238       {ECO:0000244|PDB:3P1A}.
FT   STRAND      239    241       {ECO:0000244|PDB:3P1A}.
FT   HELIX       243    245       {ECO:0000244|PDB:3P1A}.
FT   STRAND      247    249       {ECO:0000244|PDB:3P1A}.
FT   HELIX       271    273       {ECO:0000244|PDB:3P1A}.
FT   HELIX       276    280       {ECO:0000244|PDB:3P1A}.
FT   HELIX       286    301       {ECO:0000244|PDB:3P1A}.
FT   HELIX       309    315       {ECO:0000244|PDB:3P1A}.
FT   TURN        316    318       {ECO:0000244|PDB:3P1A}.
FT   HELIX       322    325       {ECO:0000244|PDB:3P1A}.
FT   HELIX       330    339       {ECO:0000244|PDB:3P1A}.
FT   TURN        344    346       {ECO:0000244|PDB:3P1A}.
FT   HELIX       350    354       {ECO:0000244|PDB:3P1A}.
FT   HELIX       357    359       {ECO:0000244|PDB:3P1A}.
SQ   SEQUENCE   499 AA;  54521 MW;  4DF28A5965265567 CRC64;
     MLERPPALAM PMPTEGTPPP LSGTPIPVPA YFRHAEPGFS LKRPRGLSRS LPPPPPAKGS
     IPISRLFPPR TPGWHQLQPR RVSFRGEASE TLQSPGYDPS RPESFFQQSF QRLSRLGHGS
     YGEVFKVRSK EDGRLYAVKR SMSPFRGPKD RARKLAEVGS HEKVGQHPCC VRLEQAWEEG
     GILYLQTELC GPSLQQHCEA WGASLPEAQV WGYLRDTLLA LAHLHSQGLV HLDVKPANIF
     LGPRGRCKLG DFGLLVELGT AGAGEVQEGD PRYMAPELLQ GSYGTAADVF SLGLTILEVA
     CNMELPHGGE GWQQLRQGYL PPEFTAGLSS ELRSVLVMML EPDPKLRATA EALLALPVLR
     QPRAWGVLWC MAAEALSRGW ALWQALLALL CWLWHGLAHP ASWLQPLGPP ATPPGSPPCS
     LLLDSSLSSN WDDDSLGPSL SPEAVLARTV GSTSTPRSRC TPRDALDLSD INSEPPRGSF
     PSFEPRNLLS LFEDTLDPT
//
